Scientific Advisory Board
Dr. Francesco Marincola - MD
Dr. Marincola is considered one of the world's leading tumor immunologists. He was the chief of the Infectious Disease and Immunogenetics section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was also the founder and editor-in-chief of the, Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of Immunotherapy, Journal of Immunology, Tumori, Clinical Cancer Research, Biological Therapy, Cancer Immunology and Immunotherapy. Additionally, he is a founding member of the Society for Immunotherapy of Cancer.
Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a senior staff scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells in metastatic melanoma. The focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics Laboratory is recognized nationally and internationally for its cutting edge technologies applied to the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.
Dr. Vijay Mahant, MS, PhD.
Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate degree from MD Anderson in Houston TX. Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics. He has held executive positions and serves as the founder/co-founder of diagnostic companies with diverse experiences in research and development including auto genomics, Medi-Lyte and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.
Dr. Mahant’s work can be seen all over the world in leading cancer institutions, by using his cutting edge genetic and diagnostic equipment. He has been at the forefront of liquid biopsy and circulating tumor cell movement(s). His passions include: ways to match tumors with specific drugs that might be "off label" and to create better early detection diagnostic tests.
Dr. Phillip S. Kim PhD.
Dr. Kim was awarded the Human Genetics Fellowship by the National Institute of Health (NIH) at, Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of Geno-dynamics system to investigate gene function.
At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/targeted diagnostic applications with prognostic, predictive and a monitoring tools for oncology and autoimmune diseases.
His work includes: managing planning and execution of technical projects, clinical trials, science and technology communications, research collaborations and KOL (Key Opinion Leader) relationships, and publications.
He is the inventor of the, Immune-Pod, which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific to individual tumors for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using Immuno-Pod maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous synthetic met ex vivo seamlessly integrated for each patient.
Dr. Kim’s valuable insight at CHIPSA will help guide decisions for precision medicine and specific immune response for all patients.